N-adamantylbenzotriazoles, exhibiting anti-influenza a virus activity and method for production thereof

FIELD: chemistry.

SUBSTANCE: invention relates to N-adamantylbenzotriazole derivatives

and where R1 and R2 are hydrogen or a nitro group. The invention also relates to a method of producing the compound of formulae 1 and 2.

EFFECT: obtaining novel N-adamantylbenzotriazole derivatives which exhibit anti-influenza A virus activity.

3 cl, 5 ex

 

The invention relates to the field of medicinal chemistry, chemistry of isoladamente that can be considered as a promising candidate substances for the role of medicinal antiviral substances used for the treatment of diseases caused by influenza A virus, including pandemichesky dangerous strains of the H1N1 virus. The invention can be used in the manufacture of drugs used in the treatment of diseases caused by pathogens of viral infections.

The technical result of the claimed method is the synthesis of a series of new 1-(1-adamantyl)-4R-benzotriazole, 1-(1-adamantyl)-5R-benzotriazole, 2-(1-adamantyl)-4R-benzotriazole, 2-(1-adamantyl)-5R-benzotriazole (R=H, NO2) exhibiting activity against influenza A virus, as well as development of methods for the synthesis of 1-(1-adamantyl)-1H-benzotriazoles from NH-benzotriazole (the unsubstituted benzotriazole, 4-nitrobenzothiazole and 5-nitrobenzothiazole) and equimolar amount of 1-adamantanol in the environment of 94% sulfuric acid at 25°C for 3-4 hours and 2-(1-adamantyl)-2H-benzotriazoles from equimolar quantities of NH-benzotriazole and 1-adamantanol by long boiling in carbon tetrachloride in the presence of minor amounts 94%sulfuric acid.

The first known antiviral drugs - derivatives of adamantane was amantadine (1-amino�Diamanten). He started a whole class of antiviral drugs containing molecular structure adamantly fragment. In the USSR, instead of amantadine in practice of treatment of influenza infection was introduced more effective and less toxic drug rimantadine [1, 2].

Amantadine and rimantadine have the same target: adamantanemethylamine website viral protein M2 Pro-Ser. However, drug-resistant viral strains that cause influenza pandemic in the 21st century, such as the influenza A (H1N1) resistant to the above drugs. In this regard, are extremely relevant to the search and development of new, active against influenza A drugs similar to amantadine and rimantadine mechanism of action.

A promising direction of development of more effective drugs - analogs of amantadine and rimantadine is synthesis adamantyl derivatives of five-membered nitrogen-containing heterocycles - azole. Many of the compounds of this structure showed high antiviral activity, metabolic stability and relatively low toxicity [3-6]. A method of obtaining some adamantanemethanol, adamantanemethanol, adamantyl-1,2,4-triazoles of administeration by heating dehydroalanine and meet�their NH-heterocycles in the absence of solvent [4]. Another approach to the synthesis of admintration was adamantylamine azole 1-adamantanol in environments with high acidity [5, 6].

A method of producing 2-(1-adamantyl)-5-aristocrata [5], which is based on adamantylamine 5-aristocrata (RC6H4CN4H, R=H, 4-F, 3-NO2, 2-NO2) 1-adamantanol in sulfuric acid solution with a concentration of 94% by weight. The scope of the method-analogue of [5] is limited by the formation of compounds containing 5-aristocratically adamantane derivatives. This methodology was later improved in [6]. This allowed us to synthesize some new compounds: 2-(adamant-1-yl)-tetrazole containing substituents of different nature in regulation 5 tetrazole cycle, as well as some panellinia 1-(adamant-1-yl)-1,2,4-triazoles [6]. The method described above does not allow to synthesize N-adamantylindiazoles.

The known method [6], which is achieved in the claimed invention technical result and total stage adamantylamine is the closest and selected as a prototype.

The disadvantages of this method are the low yield of the final products, they are not enough high quality through the use of not optimal acidic environments under adamantylamine. In the prototype [6] also investigated the possibility of adamantios�of 1,2,3-triazole, its derivatives and related benzenetoluene analogues in the above-mentioned conditions. Under adamantylidene azoles in the known method [6] is used or sulphuric acid with a concentration of 94% wt., either the system sulfuric acid : acetic acid in a weight ratio of 4:1. When using the known method [6] to adamantylamine 5R-tetrazoles with various substituents R every time you need to find the optimal pH. Note that all currently known methods of direct adamantylamine azole 1-adamantanol in acidic environments, including the method described in the prototype [6], allowed to get only one possible N-adamantyl of regioisomers.

The inventive method compensates for the above-mentioned disadvantages of the prototype [6].

The technical result of the claimed method is the synthesis of N-adamantylindiazoles exhibiting activity against influenza A virus, having General formulas 1 and 2 [1-(1-adamantyl)-1H-benzotriazoles 1 and 2-(1-adamantyl)-2H-benzotriazoles 2],

as well as development of methods for the synthesis of 1-(1-adamantyl)-1H-benzotriazole 1 from NH-benzotriazole (the unsubstituted benzotriazole, 4-nitrobenzothiazole and 5-nitrobenzothiazole) and equimolar amount of 1-adamantanol in the environment of 94% sulfuric acid at 25°C for 3-4 hours (Scheme 1)

and 2-(1-adamantyl)-2H-benzotriazole 2 of equimolar quantities of NH-benzotriazole and 1-adamantanol by long boiling in carbon tetrachloride in the presence of small amounts of 94% sulfuric acid (Scheme 2), followed by separation of the target product by crystallization.

Said technical result is achieved in that in 94% sulfuric acid, the reaction of NH-benzotriazole 1-adamantanol flows regiospecific with the formation of the corresponding 1-(1-adamantyl)-1,2,3-benzotriazole (1), while in boiling carbon tetrachloride with the addition of several drops of sulfuric acid starting compounds react with the compound 1-adamantanol with the formation of mainly 2-(1-adamantyl)-1,2,3-benzotriazole (2) with a small admixture (according to TLC) isomers 1. The claimed technical result allows us to preparative quantities to obtain both regioisomer N-adamantylindiazoles.

When dissolved in concentrated sulphuric acid 2-(1-adamantyl)-1,2,3-benzotriazoles (2), according to TLC, rapidly degraded to the parent compound, which in turn are converted further into the compounds (1). Found methods to obtain the compounds (1) and (2) provide satisfactory yields of the reaction products and simpler in design than previously published IU�odes - the alkylation of trimethylsilyl derivative of 1,2,3-benzotriazole 1-chloroadamantane in the presence ll3[7] or alkylation of 1,2,3-benzotriazole 1-bromoguanine in an autoclave at 190-200°C [8]. The claimed method of obtaining compounds 1 and 2 is safe and can be used for producing large quantities of these compounds, active against influenza virus A.

Study of antiviral activity of compounds 1 and 2, prepared by the claimed method were performed in the laboratory of molecular basis of chemotherapy, the research Institute of Influenza, Ministry of health. For in vitro experiments we used influenza virus A/Puerto Rico 8/34 (H1N1). As a result of researches it is shown that N-adamantylindiazoles 1 and 2 possess antiviral activity greater than the standard - rimantadine.

The inventive method was tested in the laboratory at St. Petersburg state University and St. Petersburg state technological Institute (technical University) and the research Institute of Influenza of the Ministry of health of the Russian Federation.

The results of testing obtained in real time, presented in the form of concrete examples:

Example 1

1-(1-Adamantyl)-1,2,3-benzotriazole. 2.98 g (0.025 mol) of 1,2,3-benzotriazole and 3.8 g (0.025 mol) of 1-adamantanol was dissolved in 50 ml of 94% sulfuric acid and was kept for 4 hours at room Tempe�the atur. The reaction mass was poured into 1 l of ice water, the precipitate of the target compound was filtered. The yield 4.7 g (74%). So a MP 149-151°C (from ethanol). The NMR spectrum1H (400 MHz, CDCl3), δ, M. D.: 1.89 (6H, Ad), 2.35 (3H, Ad), 2.54 (6H, Ad), 7.33-7.44 m, 7.83 d, 8.09 d (4H, benzene ring). The NMR spectrum13C (100 MHz, CDCl3), δ, M. D.: 29.63, 36.17, 42.12, 61.52 (adamantyl), 112.35, 120.31, 123.26, 126.16, 131.63, 147.00 (the benzotriazole). Found, %: C 75.69; H 7.52; N, 16.34. C16H19N3. Calculated, %: 75.84; H 7.57; N, 16.59.

Example 2

1-(1-Adamantyl)-4-nitro-1,2,3-benzotriazole. Obtained analogously from 0.82 g (0.005 mol) of 4-nitro-1,2,3-benzotriazole and 0.76 g (0.005 mol) of 1-adamantanol in 25 ml of 94% sulfuric acid. Extract 1.5 hours. The yield 1.33 g (89%). T. PL. 227 to 229°C (from toluene). The NMR spectrum1H (400 MHz, CDCl3), δ, M. D.: 1.91 (6H, Ad), 2.39 (3H, Ad), 2.56 (6H, Ad), 7.58 t, 8.23 t (3H, benzene ring). Spectrum 13C NMR (100 MHz, CDCl3), δ, M. D.: 29.60, 35.98, 42.31, 62.99 (adamantyl), 119.04, 120.55, 125.30, 134.098, 139.59 (the benzotriazole). Found, %: C 64.89; H 6.34; N, 19.21. C16H18N4O2. Calculated, %: C 64.40; H 6.09; N, 18.78.

Example 3

1-(1-Adamantyl)-5-nitro-1,2,3-benzotriazole. Obtained analogously from 0.66 g (0.004 mol) of 4-nitro-1,2,3-benzotriazole and 0.61 g (0.004 mol) of 1-adamantanol in 25 ml of 94% sulfuric acid. Excerpt 3 hours. Technical product (0.79 g, 66%) was purified by chromatographytandem on a column (silica gel 200 L/250µ company Chemapol, eluent - chloroform), evaporated the solvent, the residue of paracrystalline�see a significant from toluene and obtained 0.13 g of product (11%). So a MP 240-243°C. the NMR Spectrum1H (400 MHz, CDCl3), δ, M. D.: 1.93 (6H, Ad), 2.41 (3H, Ad), 2.57 (6H, Ad), 8.22 K, 8.78 (3H, benzene ring). The NMR spectrum13C (100 MHz, CDCl3), δ, M. D.: 29.60, 35.95, 42.44, 63.19 (adamantyl), 109.41, 118.44, 121.01, 130.71, 145.39, 149.04 (the benzotriazole). Found, %: C Is At 64.12; H 6.38; N, 18.52. C16H18N4O2. Calculated, %: C 64.40; H 6.09; N, 18.78.

Example 4

2-(1-Adamantyl)-1,2,3-benzotriazole. 0.6 g (0.005 mol) of 1,2,3-benzotriazole and 0.76 g (0.005 mol) of 1-adamantanol was dissolved in 30 ml of CCL4was added 4 drops of 94% sulfuric acid and boiled for 30 hours to reflux. The reaction mass was diluted with 20 ml of CCl4was washed with 2% aqueous solution of Na2CO3and water, the solvent was evaporated. The residue (1.2 g) which also contained according to TLC 1H-isomer, recrystallized from aqueous ethanol and extracted the desired product. The yield 0.66 g (52%). So a MP 102-103°C [5]. The NMR spectrum1H (400 MHz, CDCl3), δ, M. D.: 1.86 (6H, Ad), 2.33 (3H, Ad), 2.48 (6H, Ad), 7.38 kV, 7.90 kV (4H, benzene ring). The NMR spectrum13C (100 MHz, CDCl3), δ, M. D.: 29.69, 36.08, is at 42.84, 64.67 (adamantyl), 118.07, 125.83, 143.64 (benzotriazole). Found, %: C 75.82; H 7.45; N, 16.70. C16H19N3. Calculated, %: 75.84; H 7.57; N, 16.59.

Example 5

2-(1-Adamantyl)-4-nitro-1,2,3-benzotriazole. Was prepared analogously from 0.82 g (0.005 mol) of 4-nitro-1,2,3-benzotriazole and 0.76 g (0.005 mol) of 1-adamantanol in 35 ml of CCl4with 6 drops of sulfuric acid. Exposure 72 hours. T�detailed technical product (0.88 g), also contained according to TLC 1H-isomer, recrystallized from 2-propanol and allocated target product. Yield 0.2 g (13%). So a MP 150-152°C. the NMR Spectrum1H (400 MHz, CDCl3), δ, M. D.: 1.87 (6H, Ad), 2.37 (3H, Ad), 2.54 (6H, Ad), 7.52 t, 8.29 d, 8.38 (3H, benzene ring). The NMR spectrum13C (100 MHz, CDCl3), δ, M. D.: 29.67, 35.92, 42.76, 66.52 (adamantyl), 123.85, 124.31, 126.17, 136.72, 145.95 (the benzotriazole). Found, %: C 64.46; H 6.34; N, 19.21. C16H18N4O2. Calculated, %: C 64.40; H 6.09; N, 18.78.

The claimed method of producing N-adamantylindiazoles [1-(1-adamantyl)-1H-benzotriazole 1 and 2-(1-adamantyl)-2H-benzotriazole 2 (R=H, NO2)], exhibiting activity against influenza A virus, has significant technical and economic advantages compared with the known world's level of technology: it is fireproof, because the synthesis process practically does not use combustible materials; allows to synthesize separately the two regioisomer N-adamantylindiazoles use different conditions with high output; all operations included in the process, easily scalable, this method can be used to produce large quantities of desired products.

Sources of information

1. US Pat. 3,852,352, C07 with 87/40, Dec. 3, 1974.

2. US Pat. 4,551,552, C07 with 85/11, Nov. 5, 1985.

3. Kiselev O. H. Chemotherapy drugs and chemotherapy of influenza. - St. Petersburg: Rostok", 2012. - 272.

4. EN �atent of the Russian Federation No. 2,280,032.

5. Saraev V. V., Gavrilov A. S., Hunger E. L. Administerable II. Reaction of 1-Adamantanol with tetrazolium and 5-substituted tetrazole in sulfuric acid. Phys. Org.Chem., 1999, vol. 35, ISS.7, pp. 1093-1096.

6. Zarubaev V. V. Golod, E. L., Anfimov R. M, Shtro A. A., Saraev V. V., Gavrilov S. A., Logvinov A. V., Kiselev O. I. Synthesis and anti-viral activity of is azolo-adamantanes against influenza A virus. Bioorganic & Medicinal Chemistry 2010, vol.18, p.839-848 (prototype).

7. Sasaki T., Hakamishi A., Ohno M. // Chem. Pharm. Bull. 1982. Vol.30. N 6. P. 2051-2060.

8. Gonzalez M. E., Alarcon, V., P. Cabildo, Claramunt, R. M., Sanz, D., J. Elguero // Eur. J. Med. Chem. 1985. Vol.20. # 4. P. 359-362.

1. N-Adamantylindiazoles exhibiting activity against influenza A virus, having General formulas 1 and 2 [1-(1-adamantyl)-1H-benzotriazoles 1 and 2-(1-adamantyl)-2H-benzotriazoles 2], which can be used as drugs,

where R1and R2is hydrogen or a nitro group.

2. A method of producing N-adamantylindiazoles exhibiting activity against influenza A virus, namely, that to obtain 1-(1-adamantyl)-1H-benzotriazole 1 original NH-benzotriazoles (the unsubstituted benzotriazole, 4-nitrobenzothiazole and 5-nitrobenzothiazole) was treated with equimolar amounts of 1-adamantanol in the environment of 94% sulfuric acid, after which the reaction mass is mixed with water, neutralized with an aqueous solution of sodium carbonate, the precipitated product is filtered off and purified by crystallization from aqueous e�of anola, characterized in that for obtaining the 1H-isomer 1 the reaction mass is maintained at 25°C for 3-4 hours.

3. A method of producing N-adamantylindiazoles exhibiting activity against influenza A virus, namely, that to obtain 2-(1-adamantyl)-2H-benzotriazole 2 a solution of equimolar quantities of NH-benzotriazole and 1-adamantanol in an organic solvent is heated in the presence of 94% sulfuric acid, after which the reaction mass is mixed with water, neutralized with aqueous sodium carbonate solution, separated and evaporated the organic layer, the resulting product is purified by crystallization from aqueous ethanol, characterized in that to obtain the 2H-isomer 2 as a solvent carbon tetrachloride, in which the reaction mixture was heated to boiling temperature and kept for 30-70 hours, 94% sulphuric acid taken in the ratio by carbon tetrachloride/sulphuric acid 100/1.



 

Same patents:

FIELD: medicine, pharmaceutics.

SUBSTANCE: present invention refers to specific compounds or to their therapeutically acceptable salt presented in the patent claim and representing sulphonyl benzamide derivatives. The invention also refers to a pharmaceutical composition inhibiting the activity of anti-apoptotic proteins of the family Bcl-2, containing an excipient and an effective amount of a specific sulphonyl benzamide derivative.

EFFECT: sulphonyl benzamide derivatives inhibiting the activity of anti-apoptotic Bcl-2 proteins.

2 cl, 3 tbl, 558 ex

FIELD: chemistry.

SUBSTANCE: invention relates to method of obtaining 4-(1-benzotriazolyl)-5-[1(2)-naphthoxy]phthalodinitriles from 4-bromo-5-nitrophthalodinitrile by successive substitution of bromine and nitrogroup, characterised by the fact that first, 4-bromo-5-nitrophthalodinitrile is subjected to interaction with 1(2)naphthol at temperature 20-25°C for 25-35 minutes, after which obtained product is subjected to interaction with 1-H-1,2,3-benzotriazole at temperature 60-70°C for 1-1.2 hours.

EFFECT: simplification of method of obtaining and reduction of its duration.

2 ex

FIELD: chemistry.

SUBSTANCE: described are benzotriazole compounds of formula

,

where R1=H or CH3; R2=C1-C4 alkoxy; and R3=H, CH3, CH3O, F, Cl or CF3, which absorb UV/visible light, ophthalmic device material which contains said compounds and the ophthalmic device itself, which is selected from a group consisting of an intraocular lens, a contact lens, keratoprosthesis and corneal inlay or ring.

EFFECT: improved properties.

9 cl, 6 tbl, 18 ex, 11 dwg

FIELD: chemistry.

SUBSTANCE: invention relates organic chemistry and specifically to novel pyridine amide derivatives of general formula I where n equals 1; R1 and R2 together denote a residue selected from a group consisting of -CH=N-NH- and -CH=CH-N=CH-, which is bonded in any desirable direction to the parent structure or R2 and R3 together denote a residue selected from a group consisting of -CH=N-NH-; -CR28=N-NH-; -S-C(=S)-NH-; -S-CR29=N-; -N=CR30-O-; -N=CH-NH-; -N=N-NH-; -O-CH2-O-; -CH2-CH2-CH2-NH, -O-CH2-CH2-O-; -N=CH-CH=N-; -CH=CH-CH=N-, which is bonded in any desirable direction to the parent structure, or R3 and R4 together denote a -CH=N-NH- residue, which is bonded in any desirable direction to the parent structure, or R4 and R5 together denote a -CH=N-NH- residue, which is bonded in any desirable direction to the parent structure, and the rest of the residues R1, R2, R3, R4 and R5, mutually independently, in each case denote H; where R28 denotes F; Cl; Br or I; R29 and R30, mutually independently, in each case denote -NH-C(=O)-R31; -NH2; -NH-S(=O)2-R32; -NH-C(=O)-O-R33; -S-R34; where R31, R32, R33 and R34, mutually independently, in each case denote a straight or branched, saturated, unsubstituted aliphatic C1-10 residue; R6 denotes H or denotes a straight or branched, saturated, unsubstituted aliphatic C1-10 residue; R7 denotes hydrogen or -OH; R denotes -CF3; or denotes an unsubstituted tert-butyl residue; T denotes C-R35 and U denotes C-R36, V denotes N and W denotes C-R38; where R35 and R36 denote H; where R38 denotes -NR40R41; -OR42 or -SR43; where R40, R41, R42 and R43, mutually independently, in each case denote a straight or branched, saturated, unsubstituted aliphatic C1-10 residue; or denote a saturated, unsubstituted 3-, 4-, 5-, 6-, 7-, 8- or 9-member cycloaliphatic residue, or where R40 and R41 in each case together with a nitrogen atom as a ring member which binds them together, form a saturated 6-member heterocycloaliphatic residue, optionally substituted with one R57 residue, where R57 denotes a straight or branched, saturated, unsubstituted aliphatic C1-10 residue; in each case in form of corresponding physiologically acceptable salts. The invention also relates to a method of producing a compound of formula I, a medicinal agent based on the compound of formula I and use of the compound of formula I.

EFFECT: obtaining novel amide derivatives of pyridine, useful in treating vanilloid receptor 1 mediated diseases.

25 cl, 1 tbl, 18 ex

FIELD: chemistry.

SUBSTANCE: invention describes novel carbamoyl benzotriazole derivatives of general formula , (values of radicals are given in the description), tautomers thereof and pharmaceutically acceptable salts and use thereof as endothelial lipase inhibitors.

EFFECT: improved properties of the derivatives.

11 cl, 148 ex

FIELD: chemistry.

SUBSTANCE: described is a novel compound - 1-acetyl-5,10-dioxy-5,10-dihydro-2H-anthra[2,3-D][1,2,3]triazole-7,8-dicarboxylic acid of formula , which can be used as a starting compound in synthesis of metal complexes of tetra[4,5]([6,7]1-acetyl-2H-naphtho[2,3-D][1,2,3]triazole-5,8-dione)phthalocyanine.

EFFECT: possibility of use as dyes or catalysts.

1 cl, 3 ex, 4 dwg, 1 dwg

FIELD: chemistry.

SUBSTANCE: disclosed compounds can be used as a medicinal agent having CXCR2 inhibiting properties. In formula I , X denotes -CR3=CR4-, -CR5=N-, -N=CR6-, -NR7- or -S-; R3, R4, R5 and R6 independently denote hydrogen, F, CI, Br, I; R7 denotes hydrogen; Y1, Y2, Y3 and Y4 independently denote -CR8- or nitrogen, provided that at least two of Y1, Y2, Y3 and Y4 denote -CR8-; where R8 denotes hydrogen, F, CI, Br, I; A denotes a cycloalkyl having 3, 4, 5, 6, 7 or 8 carbon atoms; a bicyclic partially saturated 9-member cycloalkyl; a bicyclic partially saturated 9-10-member heterocycle in which two atoms in the ring are oxygen atoms; phenyl; naphthyl; a 5-6-member heteroaryl in which 1-3 atoms in the ring are oxygen, sulphur and nitrogen atoms; a 9-10-member bicyclic heteroaryl in which 1-3 atoms in the ring are nitrogen, oxygen and sulphur atoms; a 6-member heterocycle in which one atom in the ring is a nitrogen atom and which can be unsubstituted or substituted with alkyl having 1, 2, 3 or 4 carbon atoms, -C(O)CH3, -C(O)CH2CH3, -C(O)cyclopropyl, -C(O)CF3 and -C(O)OC(CH3)3; where phenyl, heterocyclic or heteroaryl radical is substituted with 1, 2 or 3 radicals selected from a group consisting of F, O, Br, I, OH, CN, NO2, SCF3, SF3, alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms, where 1, 2, 3 hydrogen atoms may be substituted with fluorine atoms; cycloalkyl having 3, 4, 5 or 6 carbon atoms; alkoxy having 1, 2, 3, 4, 5 or 6 carbon atoms, where 1, 2, 3 hydrogen atoms may be substituted with fluorine atoms; -S-alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms, where 1, 2, 3 hydrogen atoms may be substituted with fluorine atoms; -NR9R10, C(O)R44, S(O)SR47, -(CH2)k-phenyl, 5-6-member heteroaryl, in which 1-3 atoms in the ring are nitrogen and sulphur atoms; where the phenyl radical may be substituted with F, CI, Br, I; R9 is an alkyl having 1, 2, 3 or 4 carbon atoms; R10 is an alkyl having 1, 2, 3 or 4 carbon atoms; R44 is an alkyl having 1, 2, 3 or 4 carbon atoms, where 1, 2, 3 hydrogen atoms may be substituted with fluorine atoms; alkoxy having 1, 2, 3 or 4 carbon atoms, cycloalkyl having 3, 4, 5 or 6 carbon atoms; R47 is an alkyl having 1, 2, 3 or 4 carbon atoms; k equals 0, 1, 2 or 3; s equals 1 or 2; B is -O-C(R11R12), -C≡C-, -CR52=CR53-, -C(R13R14)C(R15R16), -NR17-C(R18R19); R11, R12, R13, R14, R15, R16, R17, R18, R19, R52, R53 independently denote hydrogen or alkyl having 1, 2, 3 or 4 carbon atoms; D is C(O)OH, C(O)NHR21 or C(=NR58)NHR22; R21 and R22 independently denote hydrogen, -SO2-alkyl having 1, 2, 3 or 4 carbon atoms, -SO2-phenyl; R58 is OH; R1 and R2 independently denote an alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms, where the alkyl radicals are unsubstituted or substituted with 1 radical selected from a group consisting of F, Cl, Br, I, phenyl substituted with OH; or R1 and R2, taken together with a carbon atom with which they are bonded form a 3-, 4-, 5- or 6-member carbocycle. The invention also relates to use of formula I compounds in preparing a medicinal agent which has CXCR2 inhibiting properties, to a medicinal agent which containing an effective amount of the disclosed compound and having CXCR2 inhibiting properties, as well as to use of formula II compounds (formula and values of radicals are given in the formula of invention) in preparing a medicinal agent having CXCR2 inhibiting properties.

EFFECT: high effectiveness of application.

10 cl, 384 ex

FIELD: chemistry.

SUBSTANCE: invention describes novel 1,2,3-triazole derivatives of general formula: , where X denotes O or N-OH; R1 is hydrogen, fluorine, chlorine, bromine, phenyl or C1-4-alkyl, unsubstituted or substituted 1-3 times with fluorine, chlorine and bromine; R2 - R5 hydrogen; pharmaceutically acceptable salts and stereoisomers thereof and a pharmaceutical composition containing the said compounds.

EFFECT: obtaining compounds which can be used as oestrogen receptor selective modulators for treating or preventing different conditions related to oestrogen function, including: bone loss, bone fracture, osteoporosis, metastatic bone disease, Piaget's disease, periodontal disease etc.

5 cl, 7 ex

FIELD: chemistry.

SUBSTANCE: invention relates to novel anthranilic acid derivatives having inhibitory effect on production of matrix metalloprotease 13 of formula 1 , where R1 is a hydrogen atom or carboxy protective group selected from C1-3alkyl; R2 is phenyl, C3-6cycloalkyl, saturated or unsaturated 5-6-member heterocyclic group containing 1-3 heteroatoms selected from N, O, S, which can be condensed with phenyl, which can be optionally substituted with C1-6alkyl, C1-6alkoxy, acetyl, acetoxy, halogen, halogenC1-6alkyl, nitro group, hydroxyl group, CN, amino group, phenyl, saturated or unsaturated 5-6-member heterocyclic group containing 1-4 heteroatoms selected from N, O, S, which can be disubstituted with C1-6alkyl; R3 is phenyl, C3-6cycloalkyl, C5cycloalkenyl, saturated or unsaturated 5-6-member heterocyclic group containing 1-3 heteroatoms selected from N, O, S, which can be condensed with phenyl (except benzoxazole), which can be optionally substituted with C1-6alkyl, C1-6alkoxy, phenyl, acetyl, halogen, halogenC1-6alkyl, halogenC1-6alkoxy, nitro group, hydroxyl group, hydroxyC1-6alkyl, CN, acetylamino, ketone, phenoxy, benzoyl, benzyl, amino group, which can be disubstituted with C1-6alkyl, carboxy group, C1-6alkylsufonyl group or pyrrolyl; X1 is a carbonyl group or sulfonyl group; X2 is a C1-3alkylene, C2-3alkenylene or C2-3alkynylene group which can be optionally substituted with C1-3alkyl, or a bond; provided that when X1 is a sulfonyl group and X4 is a bond, X2 is a C1-3alkylene, C2-3alkenylene or C2-3alkynylene group which can be optionally substituted with C1-3alkyl; X3 is an oxygen atom or a bond; and X4 is a group with general formula -X5-X6- or -X6-X5-, where the bond on the left side of each formula is bonded to R3; and X5 is an oxygen atom, a sulphur atom, an imino group which can be optionally protected or a bond; X6 is a C1-4alkylene, C2-3alkenylene or C2-3alkynylene group or a bond, as well as to their pharmaceutically acceptable salts. The invention also relates to a matrix metalloprotease 13 production inhibitor and a therapeutic agent for making a medicinal agent for treating rheumatoid arthritis.

EFFECT: possibility of making a medicinal agent for treating rheumatoid arthritis.

8 cl, 7 tbl, 633 ex

FIELD: chemistry.

SUBSTANCE: invention refers to chemical industry, i.e. to the new chemical compounds 4-(1-benzotriazole)-5-(naphtaoxy)-phtalodinitriles of the general formula in which R stands for as the basic for synthesis of copper tetra-4-(1-benzotriazole) tetra-5(2-naphtaoxy)phthalocyanine and copper tetra-4-(1-benzotriazole) tetra-5(1-naphtaoxy)phthalocyanine which are the solvent dyes for waxes, synthetic fiber, polymers, hydrocarbons, fats, alcohols, plastic materials and resin elastic colouring.

EFFECT: end dyes are dissolved effectively in organic environments.

1 cl, 4 dwg, 5 ex

FIELD: medicine.

SUBSTANCE: drops possessing antiviral and immunomodulatory effects characterised by the fact that they represent a 95% ethanol infusion of wild strawberry leaves and fruit specified in: red raspberry fruit, mountain ash fruit, bilberry fruit, blood-red hawthorn fruit, cinnamon rose fruit; 15-25 mg of the substance in 1 ml of the infusion.

EFFECT: drops possess pronounced antiviral and immunomodulatory effects.

15 tbl, 5 ex

FIELD: chemistry.

SUBSTANCE: method includes treating crushed Echinacea purpurea (L.) Moench roots and rhizome with steam, extraction with ethyl alcohol, then steeping, stirring, steeping, draining a portion of the extract which is equal to the amount of the loaded Echinacea purpurea (L.) Moench roots and rhizome, after draining a portion of the extract, adding ethyl alcohol to the treated material, draining the whole extract; extracting crushed Echinacea purpurea (L.) Moench herbs with ethyl alcohol, steeping, then stirring, steeping, draining a portion of the extract which is equal to the amount of the loaded Echinacea purpurea (L.) Moench herbs, after draining a portion of the extract, adding ethyl alcohol to the treated herbs, draining the whole extract; all obtained extracts are mixed, cooled and filtered under certain conditions. An Echinacea purpurea (L.) Moench tincture. Use of the method to obtain an Echinacea purpurea (L.) Moench tincture.

EFFECT: method preserves the biological activity of components of the tincture and medicinal properties.

3 cl

FIELD: medicine.

SUBSTANCE: invention represents an encapsulated liposomal antiviral agent based on human interferon alpha-2b for vaginal application, characterised by the fact that each capsule is made in the form of a hollow coating, which encloses a powder excipient and liposomes distributed in the excipient, and sodium alginate, a water-soluble polymer gel former; the excipient consists of lactose, sodium chloride, 12-aqueous disodium hydrogen phosphate and sodium dihydrogen phosphate, whereas each of the liposomes represents a hollow coating containing lecithin, cholesterol and alpha-tocopherol, and a nucleus inside the coating and containing recombinant human interferon alpha-2; the ingredients of the agents are taken in a certain ratio, mg.

EFFECT: maintaining the storage activity of recombinant human interferon alpha-2 and prolonged action in vaginal application.

2 cl, 3 dwg, 6 tbl, 6 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to novel compounds of general formula (I) or their pharmaceutically acceptable salts, which possess properties of RNA-polymerase inhibitor, in particular HCV inhibitor. Such disease can be hepatitis C. In formula (I)

is selected from the group, including simple carbon-carbon bond and double carbon-carbon bond; R1 represents hydrogen atom; R2 represents hydrogen atom; R3 represents hydrogen atom; R4 is selected from the group, including

and ,

R5 is selected from the group, including hydrogen atom, C1-C6alkyl and C1-C6alkyloxy; R6 is selected from the group, including hydrogen atom, C1-C6alkyl and C1-C6alkyloxy; R7 is selected from the group, including hydrogen atom, phenyl, 5-membered heterocycle, carbocycle with 2 condensed cycles, where 5-membered heterocycle contains at least 1 heteroatom, selected from the group, consisting of N, O and S, and where phenyl, heterocycle and carbocycle with 2 condensed cycles are optionally substituted with at least one of RJ and RK.

EFFECT: compounds can be used for treatment of disease, which can be treated by HCV inhibition.

21 cl, 2 tbl, 7 ex

FIELD: chemistry.

SUBSTANCE: invention relates to organic chemistry and particularly to aminoalkyl esters of 5-methoxyindole-3-carboxylic acid and pharmacologically acceptable salts thereof of general formula (I), where R1 is cyclohexyl, C1-3alkyl; R2 is phenylthio, phenyloxy, wherein the phenyl group can have 1-2 halogen substitutes or a C1-4alkoxy group, or R2 is a 5-6-member heterocycloalkyl containing 1-2 heteroatoms selected from nitrogen and oxygen; n equals 1, 2, 3, 4; each R is independently selected from C1-4alkyl; except compounds indicated in the claim. The invention also relates to a method of producing a compound of formula (I) and use thereof.

EFFECT: obtaining novel 5-methoxyindole-3-carboxylic acid derivatives, having antiviral activity.

4 cl, 2 tbl, 12 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: claimed invention relates to such compositions and pharmaceutical compositions, which include poxviruses, and namely to those, which include extracellular enveloped viruses. Claimed invention also relates to such method, which is intended for production of poxviruses, as well as poxviruses, obtained in accordance with claimed invention. In addition, claimed invention also relates to application of claimed poxviruses and said composition for medication preparation.

EFFECT: obtaining pharmaceutical compositions, which include poxviruses.

11 cl, 3 dwg

FIELD: biotechnology.

SUBSTANCE: invention relates to novel strains of Bacillus thuringiensis B-1272 and Bacillus thuringiensis B-1273 deposited in the collection of bacteria, bacteriophages and fungi of the Federal State-Funded Institution of Science "State Research Centre of Virology and Biotechnology "Vector". The index of neutralisation of the infectious activity of virus A/H3N2 while using the preparations based on the culture fluid of any of the proposed strains is 0.5-3.2 lg.

EFFECT: strains have the ability to neutralise the infectious activity of the human influenza virus.

2 cl, 1 tbl, 8 ex

FIELD: chemistry.

SUBSTANCE: disclosed cloth is capable of inactivating viruses falling thereon even in the presence of lipids and proteins regardless of whether or not the viruses have an envelope. The cloth is capable of inactivating viruses falling thereon and includes a cloth base and fine particles of a monovalent copper compound and/or iodide fine particles, wherein the fine particles of a monovalent copper compound and/or iodide fine particles are deposited on said cloth base. The fine particles of the monovalent copper compound are particles of at least one of the following group: chloride, acetate, sulphide, iodide, bromide, peroxide and thiocyanate. The cloth is capable of inactivating different types of viruses. The viruses are inactivated even in the presence of lipids and proteins.

EFFECT: enabling virus inactivation.

14 cl, 3 dwg, 4 tbl, 13 ex

FIELD: veterinary medicine.

SUBSTANCE: vaccine against plague, adenovirus infections, parvovirus and coronavirus enteritis, leptospirosis and rabies of dogs is proposed, containing the active ingredient and targeted additives, characterised in that as the active ingredient it comprises in 1 dose of vaccine the mixture of suspension of attenuated strain of canine distemper virus SCV No. 2313 family Paramyxoviridae, genus Morbillivirus with a titre of at least 103.5 TCD50; suspension of attenuated strain of adenovirus of dogs of type 2 SCV No. 2311, family Adenoviridae, genus Mastadenovirus with a titre of at least 103.0 TCD50; suspension of attenuated strain of canine parvovirus of type 2 SCV No. 2312, family Parvoviridae, genus Parvovirus with a titre of at least 103.0 HAU; suspension of attenuated strain of canine coronavirus SCV No. 2314, family Coronaviridae, genus Coronavirus with a titre of at least 103.0 TCD50; inactivated suspension of strain of rabies of dogs ERA-CB-M20, family Rhabdoviridae, genus Lyssavirus in the amount of 1 ME, inactivated suspensions of leptospira of serogroups Icterohaemorrhagiae and Canicola taken in the mixture in equal proportions with the final concentration of each strain of at least 3×108 inactivated microbial cells in 1 dose of the vaccine.

EFFECT: invention is characterised by higher antigenic and immunogenic potency, safety, ability to create colostral immunity of high intensity, high stability in storage, high specificity in relation to different subtypes and main antigenic variants of epizootic strains of pathogens circulating in the outer environment in the territory of Russia and the CIS countries, the vaccine is environmentally friendly, does not cause dissemination of pathogenic agents.

4 cl, 13 tbl, 8 ex

FIELD: medicine.

SUBSTANCE: composition includes glutaryl histamine in an amount of 18.0-75.0 wt % as an active substance, and as auxiliary substances: microcrystalline cellulose in an amount of 18.0-71.0 wt %, sodium croscarmellose in an amount of 0.25-1.0 wt %, colloidal silicon dioxide in an amount of 0.5-2.0 wt %, calcium stearate in an amount of 0.5-2.0 wt % and lactose monohydrate. The invention also relates to a method of obtaining the said composition.

EFFECT: invention is characterised by the high bioavailability of the active component and high pharmacological activity.

4 cl, 6 tbl, 3 ex

FIELD: biotechnology.

SUBSTANCE: invention relates to a low-toxic (E)-2-(4-{[3-(2,4-dimethoxyphenyl)acrylamido]methyl}-1H-1,2,3-triazole-1-yl)-2-isopropyl-9-(4-methyl piperazine-1-yl)-3,7-dioxo-3,7-dihydro-2H-furo[3,2-g]chromen of formula (I) , having the analgesic activity in the test "acetic acid-induced writhing". The said property enables to use this compound in medicine.

EFFECT: compound of formula I is prepared from furocoumarin peucedanine contained in the plant Peucedanum morisonii.

1 tbl, 5 ex

Up!